June 08, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Petrelintide, a novel amylin analog, induces 10% weight loss, very well tolerated
NEW ORLEANS — Weekly petrelintide demonstrated clinically meaningful weight loss through 42 weeks and was well tolerated among adults with obesity or overweight without diabetes, according to results from the phase 2 ZUPREME-1 trial.Petrelintide (Roche/Zealand Pharma) is a long-acting human amylin analog that is being investigated as a once-weekly injectable medication for obesity.
764 words~3 min read
